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Induction of effective cross-reactive immunity by FMDV peptides is critically
dependent upon specific MHC-peptide-T cell interactions
E. J. GLASS & P. MILLAR AFRC Roslin Institute, Roslin, Midlothian
SUMMARY
BoCD4+ T-cell clones specific for a peptide derived from foot-and-mouth disease virus envelope
protein, VP1 (FMDV15) were generated from two responder cattle. One animal was a high and the
other was an intermediate responder in terms of both T-cell and antibody responses. However
both animals had identical major histocompatibility complex (MHC) class II DR-like types
(DRBF3,6) according to a one-dimensional isoelectric focusing method which distinguishes
DR-like alleles. In contrast, mixed lymphocyte reaction (MLR) responses indicated that they
shared only one haplotype (DRBF3) and anti-DRBF6 alloclones also differentiated between the
animals. This suggested that the animals differed at a non-DR-like locus. Restriction patterns of
FMDV-specific clones derived from these animals indicated that FMDV1 5 was presented by the
non-DR-like class II molecules associated with DRBF6. Only one clone, derived from the high
responder animal, was restricted to DRBF3. Thus products from the non-DR-like locus (probably
DQ-like) are functionally important for presentation of FMDV peptides. Furthermore the allelic
differences detected by the alloclones are also critical for peptide binding. The majority of clones
from the high responder animal recognized an immunodominant region containing a Rothbard
epitope whereas none of the clones from the intermediate responder did so. This suggests that the
region recognized by T cells, which is dependent upon MHC type, influences the B-cell response
and thus the degree of protection obtained. This has major implications for rational vaccine design
involving T- and B-cell epitopes.
INTRODUCTION
The interaction between major histocompatibility complex
(MHC) class II molecules, antigenic peptides and clonotypic
T-cell receptors (TcR) are essential to most if not all immune
responses. The role of different MHC class II loci and alleles in
Ir gene regulation of T-cell recognition is well established. In
contrast, how this control affects the outcome of an immune
response in terms of generating protective immunity, is poorly
understood. We are investigating how variations in MHC-T
cell interactions lead to differences in effective immunity using a
model system-bovine T-cell responses to a peptide derived
from foot-and-mouth disease virus (FMDV1 5)-which also
has direct practical implications.
Neutralizing antibody is believed to be the most important
effector mechanism against FMDV infection.' The major B-cell
site has been located to the loop region of virus envelope
protein (VP)12 and is present within the synthetic peptide,
FMDV1 5. Although this peptide was designed as a potential
synthetic vaccine, it has proved less successful in the host
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species than predicted by results in a small animal model.3 The
relative importance of T-cell recognition and function in
protection against the virus may be more important than
previously realized. We have shown that the synthetic peptide
contains bovine T-cell epitope(s).4 In addition other structural
proteins of the virus contain T-cell epitopes.5'6
We have shown that the recognition ofFMDV15 by bovine
T cells is under bovine MHC (BoLA) class II-restricted
control.4 Polymorphism of the expressed products of a
bovine DR-like locus alters both the magnitude of the T-cell
response and the region recognized. These locus products are
detected by a one-dimensional isoelectric focusing (IEF)
method7 and we have shown that they function as restriction
elements.8 However two animals which had the same MHC
class II DR type as defined by IEF had different T-cell and
antibody responses. Restriction patterns with cell lines derived
from these two animals suggested that they may in fact express
different MHC class II types.4 This paper extends these findings
and shows that other class II products act as restriction
elements important in presenting FMDV15. Furthermore we
suggest that MHC control of the cellular response is important
in determining the humoral response. Different T-cell epitopes
may be more or less effective in inducing appropriate T-cell help
for B cells to make neutralizing antibody.
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MATERIALS AND METHODS
Peptides
Peptides were prepared by solid-phase synthesis9 and corre-
spond to VP1 sequences ofFMDV strain 01K (type 0, subtype
1, strain Kaufbeuren). 10 Peptides which combine discontinuous
regions of the protein (e.g. FMDV1 5) were prepared in a single
synthesis. FMDV1 5 represents the peptide used by Di Marchi
et al.3 and consists of the 200-213 sequence and the 140-158
sequence of VP1 coupled by a Pro-Pro-Ser spacer together
with a dicysteine at the N-terminus and Pro-Cys-Gly at the
C-terminus. FMDV19 comprises the 141-158 sequence
together with Pro-Cys-Gly at the C-terminus. FMDV1.4, 1.3
and 1.2 span regions of the 141-158 sequence and comprise
149-160, 149-163 and 152-163 respectively. FMDV26
comprises the 200-213 sequence only. FMDV15, 19 and 26
were kindly donated by Dr R. DiMarchi (Eli Lilly, Indiana-
polis, IN) and FMDV1.2-1.4 were kindly donated by Dr T.
Doel (AFRC IAH, Pirbright, U.K.). The region 140-158
contains structural features associated with T-cell epitopes
including amphipathic a helices and a Rothbard predicted
epitope," 154-157 (KVAR).12
Animals
Friesian (Bos taurus) castrated male or female cattle from the
research station's herd were used for this study. All the animals
were clinically normal and over 6 months of age. For
immunization castrated male cattle between 9 and 12 months
were chosen.
Immunization
The animals were immunized subcutaneously with 1 mg
FMDV15 (first immunization, week 0), 0-2 mg FMDV15
(second immunization, week 13) and 1 mg FMDV5 (third
immunization, week 25) in 1: 1 ratio of saline and non-
ulcerative incomplete Freund's adjuvant courtesy of Mr B. D.
Morris (Guildhay antisera, University of Surrey, U.K.).
Preparation ofperipheral blood mononuclear cells (PBMC)
PBMC were separated on Ficoll-Hypaque (Pharmacia,
Uppsala, Sweden) as previously described13 and were
resuspended in RPMI-1640 supplemented with 25 mm
HEPES, 2mm glutamine, 10% fetal calf serum (FCS),
5 x 10-5 M 2-mercaptoethanol and 50 yig/ml gentamycin
(Gibco BRL, Inchinan, U.K.) (complete medium).
Generation ofFMD V15-specific BoCD4 + clones
BoCD4 + clones were generated from PBMC from two selected
animals as described in the text which produced both T-cell and
antibody responses to FMDV15 following immunization. The
initial in vitro expansion was essentially as described previously
for FMDV-specific T-cell lines.4 PBMC were first cultured with
FMDV15 (1 ug/ml) for 7 days, followed by recombinant
human interleukin-2 (rhIL-2) (20 U/ml) for a further 7 days.
The blasting cells were then cloned at 0 3 cells/well in 96-well
round-bottomed plates together with irradiated autologous
PBMC (105/ml), rhIL-2 (20 U/ml) and peptide (1 Mg/ml). They
were fed at 7-day intervals with irradiated autologous PBMC,
rhIL-2 and peptide. After 14-21 days growing clones were split
and after a further 7 days were transferred to 24-well
plates (Nunc, Gibco BRL). Clones with rapidly growing
characteristics were then transferred to 6-well plates. The
phenotype of the clones was determined by indirect immuno-
fluorescence and FACS analysed according to Glass and
Spooner.14 They were >90% BoCD4+, as detected by the
monoclonal antibody (mAb) IL-Al 1;15 BoCD8-, as detected
by the mAb IL-A5 116 and MHC class II + (8-55%), as detected
by the mAb Ji 1.17 The clones were MHC class II restricted as
determined by blocking with anti-MHC class II and anti-MHC
class I mAb as previously described.18
Proliferation assays
These were essentially as described elsewhere.'9 Clones were
rested prior to use in proliferation assays for 6-8 days after the
addition of antigen-presenting cells (APC) and FMDV15.
Briefly, T-cell clones (1 x 104/well) together with irradiated
PBMC (6 x 104/well) (5000 rads) and rhIL-2 (10 U/ml) were
incubated with antigen, and cell proliferation measured after 3
days by a final 6-hr pulse with [3H]thymidine (Amersham
International, Amersham, U.K.) and uptake assessed by liquid
scintillation counting.
MLR
These were carried out as described previously.20 Responders
and stimulators were cultured together for 6 days and prolifera-
tion measured as described above.
BoLA class I typing
A micro-lymphocytotoxicity test as described by Spooner et
al.2' was used to detect all of the internationally agreed
workshop specificities.22
BoLA class II typing by one-dimensional IEF
IEF and immunoprecipitation of BoLA class II antigens were
carried out according to the method of Joosten et al.7 using a
rabbit anti-human HLA-DR antiserum (this antiserum was a
kind gift from Dr H. Ploegh, the Netherlands Cancer Institute,
the Netherlands) which precipitates BoLA class II molecules.
Distinct banding patterns are seen for the P chain with two
bands per haplotype; a chains appear to be mainly non-
polymorphic. The patterns are currently designated as DRBF
types according to the fifth BoLA workshop.23
BoLA class II typing by BoLA class II-specific alloreactive
clones
This was carried out essentially as described by Glass, Millar
and Oliver.20 Briefly, bovine BoLA class II-specific clones were
generated from responder PBMC, differing from stimulator
PBMC by BoLA class II type (as defined by the above IEF
method) and not BoLA class I type (as defined by the
above micro-lymphocytotoxicity test). For this study, the
responder:stimulator pair was class II typed as DRBF7,8:
DRBF6,7 and both class I typed as A18 (A6), A31. The
phenotypes of the alloreactive T-cell clones were determined as
described above and were similar to the FMDV-specific clones.
They were MHC class II restricted as described previously.20
Proliferation assay with alloreactive clones
Clones (2 x 104/well) and a panel of BoLA class I and IEF
class II typed stimulators (irradiated PBMC) (12 x 105/well)
were incubated together with 20U/ml rhIL-2 in quadrupli-
cate cultures in 96-well flat-bottomed plates (Nunc, Gibco
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BRL). Cell proliferation was measured after 72 hr as
described above. C.p.m. of blasts alone were usually less than
200 c.p.m.
Serum neutralization tests (SNT)
SNT were carried out by the FMD World Reference
Laboratory (AFRC IAH Pirbright) as described by Mulcahy
et al.24 Virus neutralization titres are expressed as the reciprocal
of the lowest dilution of serum which permitted any plaque
formation when pretitrated FMDV (serotype O1BFS) was
incubated with IB-RS-2 cells.
RESULTS
Although animals 10795 and 10814 were BoLA class II typed
by IEF as DRBF3,6, their immunological responses to
immunization with a peptide derived from FMDV VP1,
FMDV15, were markedly different. Peripheral blood T cells
from 10795 consistently showed significantly higher responses
to FMDV15, FMDV19 and FMDV1.4 compared to those
from 10814 (Table 1). Furthermore antibody levels correlated
with T-cell responses. SNT from 10795 were higher after
the second and third immunization than those from 10814
(Table 1).
The one-dimensional IEF method appears to detect
polymorphism in expressed f chains from one locus.7 However
cells from 10795 and 10814 reacted strongly to one another in
one-way MLR (Table 2). Neither reacted to stimulator cells
(11179) typed by one-dimensional IEF as homozygous for
DRBF3 which suggested that they express identical BoLA class
II molecules associated with DRBF3. Thus they must express
differences in their BoLA class II molecules associated with
DRBF6 which can be recognized by T cells.
To investigate these differences further, BoCD4 + alloclones
were generated which recognize DRBF6. Two distinct sets of
clones were produced. The first set ('A') reacted to the majority
of DRBF6-expressing stimulators whereas the second set ('B')
had a more restricted recognition pattern (Table 3). Neither set
recognized any non-DRBF6-expressing stimulators but did not
react to all DRBF6 stimulators. Of particular importance
Table 1. Comparison of T-cell and antibody responses by 10795 and
10814
A c.p.m. x 10-3*
Peak T-cell response to 1 Mg/ml
Peak
Animal Immunization FMDV15 FMDV19 FMDV1.4 SNT
10795 1 46 NDt ND 64
2 58 28 ND 1024
3 145 123 62 > 1400
10814 1 9 ND ND 64
2 13 11 ND 355
3 23 20 4 355
* A c.p.m., c.p.m. of test - c.p.m. with medium alone.
t ND, not done.
Table 2. MLR responses with 10795 and 10814
Stimulators (DRBF class II type; BoLA class I type)
(c.p.m.)
10795 10814
(DRBF3,6; (DRBF3,6; 11179
Responders All,A36(A20)) All,A32) (DRBF3; All)
10795 1136 52,235 1064
10814 47,739 492 569
11179 16,392 40,003 1956
10795 was only positive with the 'A' set ofclones whereas 10814
was positive with both 'A' and 'B' sets of clones. A further
allo clone ('C') had an even more restricted pattern-it only
reacted to three DRBF6-expressing stimulators, including
10814, in the panel used. However it also reacted with a
non-DRBF6-expressing stimulator, 10552 (typed by IEF as
DRBF4,8).
Next, BoCD4 + FMDV-specific clones were generated from
10795 and 10814. The clones only proliferated to antigen in the
presence of appropriate APC; no responses to allo APC in the
absence of antigen were seen. Their restriction patterns were
analysed using a panel ofIEF and alloclone defined APC. All of
the clones tested, except one (see below), were restricted to the
DRBF6 haplotype (Figs 1 and 2). The sets of clones derived
from the two animals had very distinct patterns of response
with respect to DRBF6-expressing APC. All clones from 10814
only reacted to FMDV15 in the presence of self-APC or APC
which were positive for both 'A' and 'B' sets of alloclones
(Fig. 1).
Although all the clones from 10814 had identical restriction
patterns, the DRBF6 haplotype-restricted clones from 10795
fell into three distinct groups. Of the 26 clones which were
tested, 25 reacted to FMDV15 in the presence of self-APC or
APC which stimulated the 'A' set of alloclones (see Fig. 2a-d
for the patterns of selected clones). Fifteen clones were more
extensively tested with a larger panel of typed APC. Six of
these reacted with an additional three DRBF6 expressing APC
(Fig. 2a). Of the nine clones which did not react with this group
of three APC, two clones reacted with another DRBF6 + APC
(5608) (Fig. 2b) and two reacted with 10554 (Fig. 2c). Both
APC were negative with all alloclones. Two clones were
tested and were positive with 10552 which is DRBF4,8 and
DRBF6- but which was positive with alloclone 'C' (see above)
(see Fig. 2d for one of them). Unfortunately the animal is no
longer available to carry out further testing. Two APC which
were DRBF6 + but not recognized by any of the alloclones did
not act as APC for any of the FMDV-specific clones. Only one
clone tested was DRBF3 restricted (Fig. 2e). This clone was the
only 10795-derived clone which responded to FMDV15 when
presented by 10814 or 11057; both APC must be presenting
FMDV15 via MHC class II molecules associated with the
DRBF3 haplotype and not the DRBF6 haplotype.
Many of the clones were also tested to see which region(s) of
FMDV15 they recognized. Of the 19 clones tested from 10795,
only one did not recognize FMDVI9 (Table 4). Furthermore,
the response to FMDV19 with 17 of these clones closely
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Table 3. Proliferative responses by allo (anti-DRBF6) clones
A c.p.m.
Stimulator DRBF type BoLA class I type 'A' type clone 'B' type clone 'C' type clone
3990 6,7 A18(A6),A31 127,389* 195,175 98,803
10795 6,3 Al1,A36(A20) 104,623 545 2278
10774 6,8 A36(A20),A31 117,496 3274 -38
5689 6,8 A36(A20),A31 134,102 552 6
10814 6,3 AlIl,A32 100,392 277,344 53,157
7500 6,11 A32,A31 117,490 160,750 4039
11057 6,3 AI I,A32 133,455 140,807 1996
10095 6,5 AIO,A31 232,006 138,090 130,976
5608 6,5 AIO,A36(A20) 2579 1394 908
5613 6,1 A 1,A36(A20) 2033 275 356
10952 6,3 A 1,A36(A20) 1098 661 ND
10554 6,7 AIO,A18(A6) 310 3290 -56
L548 6,2 A2,- 70 824 443
11048 6, , 1863 1548 2005
10785 8,11 A32,A31 881 503 -1932
10552 4,8 AIO,A31 1612 2497 100,980
* Positive responses are shown in bold type.
paralleled the response to FMDV15 (Fig. 3). Twelve clones
recognized FMDV1.2-1.4. One clone (1A-3B7) recognized
FMDV26 (Fig. 3b). The restriction pattern for this clone is
shown in Fig. 2c. Sixteen clones from 10814 were tested. The
majority (10/16) recognized FMDV19 although three clones
had a much lower response to this peptide (Table 4 and Fig. 3).
Six clones did not recognize FMDV19 or FMDV26. Of
particular importance, none of the clones derived from 10814
recognized any of the shorter peptides.
DISCUSSION
This study extends our findings on bovine T-cell recognition of
a putative vaccinal peptide, FMDV15 in relation to BoLA class
II type. FMDV-specific clones from two animals with
apparently identical class II type, as detected by a one-
dimensional IEF method, were characterized in relation to
their restriction patterns and antigen specificity. Although
these two animals had identical DRBF type they produced
different T-cell and antibody responses. One animal was a high
responder and the other was an intermediate responder.
Subsequently, positive MLR responses between these two
animals indicated that they could not in fact be identical for all
expressed class II molecules (Table 2). Furthermore in a
previous study we showed that FMDV-specific lines derived
from the two animals described here had slightly different class
II restriction patterns.4 At present the only reliable method for
detecting expressed polymorphisms of bovine class II molecules
is a one-dimensional IEF technique which we have shown
detects functionally important restriction elements.4'8'20 It is
assumed that this method detects products from a DR-like
locus as the expressed polymorphisms correlate with
DR-associated restriction fragment length polymorphism
(RFLP) differences.25 However evidence at both the genomic
level26'27 and with cDNA28-30 indicates that at least another
locus is expressed and is polymorphic. Furthermore there appear
to be strong associations between DR and DQ haplotypes.23'25
The MLR results with the two FMDV-immunized animals
indicated that they were identical for all class II molecules
associated with DRBF3. Certainly no splits in DRBF3 have
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Figure 1. Proliferative responses by a typical FMDV15-specific clone derived from 10814 to FMDV1 5 (1 pg/ml) with a panel of APC.
DRBF types and alloclass II types of APC donors are shown. ND, not done; (-) negative response. SD < 10%.
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Figure 2. Proliferative responses by typical FMDVl5-specific clones derived from 10795 to FMDV15 (1 yg/ml) with a panel of APC.
As Fig. 1, DRBF and alloclass II types ofAPC donors are shown. (a-e) The variation in restriction patterns seen with different clones.
The frequency of clones with these patterns is shown.
been detected by anti-DRBF3 alloclones20 and the latest
BoLA workshop reports a single haplotype associated with
DRBF3.23 Analysis of the restriction patterns of the FMDV-
specific clones revealed that only one was restricted to DRBF3.
This is in contrast to T-cell lines generated from these two
animals which were restricted to both DRBF3 and DRBF6.4
Possibly the selection procedure for the clones biases T-cell
reactivity to certain restriction elements or the frequency of
DRBF3-restricted T cells is much lower than that for DRBF6.
Limiting dilution analysis of the bulk T-cell population with
DRBF6 or DRBF3 homozygous APC may help to answer this
question.
The results with both the alloclones and FMDV-specific
clones suggest that DRBF6 is not associated with a single
haplotype. There are several possibilities to explain these
results. DRBF6 has several variants which have identical pI,
share allo-epitopes and have distinct allo-epitopes, and have
different peptide-binding sites. This is unlikely as most of the
amino acid changes that affect binding of peptide also alter the
charge.3' Furthermore, although it is possible for two ,B chains
0
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Table 4. Peptide recognition by FMDV clones
A c.p.m.
10795 clones 10814 clones
Frequency* Frequency
Peptides 12/19 5/19 1/19 1/19 7/16 3/16 6/16
FMDV15 59,813t 21,584 27,976 8476 100,767 175,362 11,381
FMDV19 43,511 17,703 5035 990 101,447 243,341 -2978
FMDV26 -456 127 -288 7001 3834 -3862 -4359
FMDV1.2 5140 485 1124 -79 492 601 759
FMDV1.3 24,314 226 3542 195 -683 2702 -68
FMDV1.4 39,110 16 668 374 1027 -1691 546
* Frequency refers to the number of clones tested which showed the pattern.
t Positive responses are shown in bold type.
to have identical pI (e.g. HLA Dw4 and Dw1432), it has never
been reported that two variants of an allelic product have
identical pl. Alternatively the 'A' type alloclones may see one
molecule and the 'B' type alloclones another. Thus 10814 would
express both the 'A' molecule and the 'B' molecule. However
the FMDV-specific clones derived from 10795 which are
restricted to 'A' do not recognize FMDV15 in association
with 10814. It seems more likely that the reaction patterns
seen with the alloclones are revealing a second locus which
codes for products able to present FMDV15. These second
locus products are in strong linkage equilibrium with DRBF6.
Certainly there are several different RFLP DQ types associated
with DRBF6. 23,25
Several of the clones derived from 10795 had a different
restriction pattern in that they also reacted with additional
DRBF6 expressing APC. This suggests that there must be
further class II alleles which are associated with DRBF6 and
are able to bind and present FMDV15.
Thus the IEF method does not distinguish all functionally
important restriction elements. The evidence from both the
alloclones and the FMDV-specific clones suggests that other
locus products also act as restriction elements. Currently we are
6o- (a) 10- (b)
E 40-
o ~~~~~~~~~~~~~~~~~6-
C30-0
4-0, 20
a.
developing new methods to detect these functionally important
molecules.33
The specificity of the T-cell clones from the two animals was
also influenced by the usage of different restriction elements.
The majority of clones from 10795 recognized peptides
containing the Rothbard predicted epitope. This specificity
mirrored the responses found with bulk PBMC.4 Some of the
clones did not respond to the shorter peptides and must
therefore be recognizing T-cell epitope(s) within the sequence
140-149. One clone reacted with FMDV26 which does not
contain any features currently associated with T-cell epitopes.
In contrast, none of the clones derived from 10814 recognized
the shorter peptides and several clones did not even recognize
FMDV19. As these clones did not recognize FMDV26, they
must be recognizing an epitope which is only present in the
40-mer peptide-the most likely candidate would be around
the PPS spacer.
The reactivities of the 10795 clones in relation to their
restriction patterns are more complex than those with 10814.
This may be because 10795 expresses several restriction
elements which can bind and present FMDV15 whereas with
10184 only one restriction element can do so. It might have
200 -
150 -
100 -
0 v
0.1 0.5 1 2 0-1 0-5 1
Peptide (ILg/ml) Peptide (glg/tnl)
(C)
2 0-1 0-5 1
Peptide (gg/ml)
Figure 3. Proliferative responses by different T-cell clones to FMDV peptides. (a and b) were derived from 10795 and (c) from 10814.
(0) FMDV15; (O) FMDV19; (A) FMDV1.4; (0) FMDV1.3; (*) FMDVI.2; (A) FMDV26. SD < 10%.
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been expected that the clones with slightly different patterns
might have recognized different regions of FMDV15. More
defined peptides may answer this.
If the frequencies of the clonal specificities mirror those in
the bulk population this may explain why 10814 has a lower
T-cell response than 10795. The region containing the
Rothbard predicted epitope appears to be immunodominant4
and as suggested by Kojima et al.34 the ability to recognize
immunodominant epitopes may determine the magnitude of
response to the whole peptide. In addition the antibody
responses by 10795 are much higher than those for 10814,
suggesting that the region recognized by T cells influences the
humoral response. Possibly the type of T cells induced may be
different. Although the division into Thl and Th2 for BoCD4+
T cells has not been reported it is likely that differential
cytokine production plays an important role in determining
B-cell activity.35 It has been reported that the generation ofThl
or Th2 responses to a single peptide in mice is dependent upon
MHC class II type.36 Amadori et al.37 have shown a correlation
between protection against FMDV and production of IL-2 and
interferon-y by T cells in vitro. Furthermore through the
cytokine network, T cells can determine the isotype and
therefore the effector function of antibody. The isotype of
antibody produced may be of particular importance in
protection against FMDV.38 Thus there may be a relationship
between the induction of protection and the interaction
between MHC-peptide-TcR. Currently we are investigating
the cytokine profiles of the different sets of clones.
In summary, we have shown that more than one BoLA class
II product is expressed per haplotype and more importantly
they act as restriction elements for FMDV1 5. Thus Ir genes are
an important consideration for vaccine design as expression of
different alleles may determine whether or not an effective
immune response is generated.
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